Method for treating cancer with a chemotherapeutic modifier
AssigneeElion Oncology, Inc.
InventorsLorenzo Leoni, Khalid Islam
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating cancer in a human subject. The method comprises: (a) orally administering eniluracil at a dose 30-60 mg/day to the subject; (b) at least after 10 hours of step (a), orally administering capecitabine at a dose about 140-700 mg/day or at a dose providing a 5-FU exposure (AUC) of approximately 1500 h*ng/ml or higher to the subject for 2-14 consecutive days; and (c) 3-14 days after step (b), repeat the steps (a) and (b). The present invention is suitable to treat colorectal cancer, gastrointestinal tract tumor, breast cancer, pancreatic cancer, head and neck cancer, lung cancer, or advanced biliary tract cancer.
Claims7
A method for treating cancer in a human subject, comprising:
- (a) orally administering eniluracil at a dose 30-60 mg/day to the subject;
- (b) at least after 10 hours of step (a), orally administering a fixed dose of capecitabine at about 140-700 mg/day to the subject for 2 to 14 consecutive days or a dose of capecitabine providing a 5-FU exposure (AUC) of approximately 1500 h*ng/ml or higher;
- and
- (c) 3 to 14 days after step (b), repeat the steps (a) and (b).
Dependencies are inferred from the claim text.